Enhancing Outcomes and Reducing Treatment Burden with Advanced Therapies in Neovascular AMD and DME : Episode 13

Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

February 21, 2025

By John Kitchens, MD
Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth

Opinion

Video

Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.

EP: 1.Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP: 2.Advantages of the molecular structure of aflibercept

EP: 3.Treat-and-Extend Strategy With Aflibercept

EP: 4.Assessing New Therapies for Retinal Diseases

EP: 5.Significance of the Higher Molar Dose of Aflibercept 8 mg

EP: 6.Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP: 7.Patient Selection for Aflibercept 8 mg

EP: 8.Faricimab Molecular Design and Role of Ang-2

EP: 9.Outcomes with Faricimab and Choosing Between the New Therapies

EP: 10.Safety Profile of New Therapies

EP: 11.Perspectives on the Usefulness of Real-world Data

EP: 12.Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

Now Viewing

EP: 13.Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

As treatments with greater durability emerge, how might they change your approach to treating neovascular age-related macular degeneration or diabetic macular edema? What impact will this have on treatment and monitoring schedules?
How will this impact workflows and clinic capacity?